Rahul N. Doshi

Dr. Rahul N. Doshi


Research Focus & Metrics

Academic Career Length

22Years (2005-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 July 2022 in Circulation: Arrhythmia and Electrophysiology
Verified
Journal Article
Closed access
PDF file
DCDaniel J. Cantillon
Daniel J. Cantillon
AGAlok Gambhir
Alok Gambhir
RBRajesh Banker
Rajesh Banker
MRMayer Rashtian
Mayer Rashtian
RDRahul N. Doshi
Rahul N. Doshi
RKReinoud E. Knops
Reinoud E. Knops
Background: Leadless pacemakers (LPs) can mitigate conventional pacemaker complications related to the transvenous leads and subcutaneous pocket surrounding the pulse generator. Although single-chamber leadless pacing has been established, multichamber pacing requires wireless bidirectional communication across multiple LPs to maintain synchrony. This preclinical study demonstrates the chronic performance of implant-to-implant (i2i) communication that achieves synchronous, dual-chamber pacing with 2 LPs. Methods: The i2i communication modality employs subthreshold electrical signals conducted between implanted LPs through the blood and myocardial tissue on a beat-by-beat basis. Right atrial and right ventricular LPs were implanted in 9 ovine subjects. The i2i transmission performance was evaluated 13 weeks after implant. Results: Right atrial and right ventricular LPs were implanted successfully and without complication in 9 ovine subjects. A total of 8715±457 right atrial-to-right ventricular and right ventricular-to-right atrial transmissions were sent per hour, with a success rate of 99.2±0.9%. Of periods with i2i communication failure when DDD pacing was not possible, 97.3±1.8% were resolved within 6 s. Conclusions: For the first time, synchronized, dual-chamber pacing has been demonstrated in a chronic preclinical feasibility study by 2 leadless pacemakers using beat-to-beat, wireless communication, achieving a success rate of 99.2%.

6 May 2022 in American Heart Journal
Verified
Journal Article
Closed access
OWOussama M. Wazni
Oussama M. Wazni
LBLucas Boersma
Lucas Boersma
JHJeff S. Healey
Jeff S. Healey
MMMoussa Mansour
Moussa Mansour
CTClaudio Tondo
Claudio Tondo
VRVivek Y. Reddy
Vivek Y. Reddy

6 August 2024 in Circulation
Verified
Journal Article
Open access
JIJames E. Ip
James E. Ip
MRMayer Rashtian
Mayer Rashtian
DEDerek V. Exner
Derek V. Exner
VRVivek Y. Reddy
Vivek Y. Reddy
RDRahul N. Doshi
Rahul N. Doshi
RKReinoud E. Knops
Reinoud E. Knops
BACKGROUND: A dual-chamber leadless pacemaker system has been designed for atrioventricular synchronous pacing using wireless, beat-to-beat, implant-to-implant (i2i) communication between distinct atrial and ventricular leadless pacemakers. The atrioventricular synchrony achieved across various ambulatory scenarios has yet to be systematically evaluated. METHODS: A prospective, single-arm, unblinded, multicenter, international clinical trial of the leadless pacemaker system was conducted in patients with a conventional dual-chamber pacing indication enrolled from February 2022 to March 2023. Leadless pacemaker systems were implanted, and 12-lead Holter electrocardiographic recordings were collected 3 months after implantation over various postures/activities: sitting, supine, left lateral recumbent, right lateral recumbent, standing, normal walk, and fast walk. An independent Holter core laboratory performed a manual adjudication of the percent of atrioventricular synchronous beats using the standard 300-millisecond PR interval limit. Atrium-to-ventricle and ventricle-to-atrium i2i communication success rates were also assessed. Post hoc summary statistics describing the relationships between atrioventricular synchrony and i2i success, posture/activity, implantation indication, atrioventricular event, and heart rate were calculated. RESULTS: In the evaluable population (n=384 of 464 enrolled [83%]; 61% male; age, 70 years; weight, 82 kg; 60% ejection fraction; 95% of beats evaluable), the mean atrioventricular synchrony of 98% of beats observed across all postures using the standard 300-millisecond limit was greater than both atrial-to-ventricular i2i (94%) and ventricular-to-atrial i2i (94%; P 95% of evaluable beats across all postures/activities, implantation indications, atrioventricular paced/sensed event combinations, and heart rate ranges (including >100 bpm). CONCLUSIONS: This dual-chamber leadless pacemaker system demonstrated atrioventricular synchrony in 98% of evaluable beats at 3 months after implantation. Atrioventricular synchrony was maintained across postures/activities and remained robust for heart rates >100 bpm.

3 June 2025 in EP Europace
Verified
Journal Article
Open access
VRVivek Y Reddy
Vivek Y Reddy
RDRahul N. Doshi
Rahul N. Doshi
JIJames E Ip
James E Ip
PDPascal Defaye
Pascal Defaye
DEDerek V Exner
Derek V Exner
RKReinoud E Knops
Reinoud E Knops
Aims: A dual-chamber leadless pacemaker (LP) system that employs distinct atrial and ventricular LP devices (ALP, VLP) has been introduced to clinical practice. Proprietary, low-energy, implant-to-implant (i2i) communication at each beat enables the devices to maintain synchronous atrioventricular sensing and pacing. We evaluated device longevities and contributing factors, such as i2i communication. Methods and results: Patients meeting dual-chamber pacing indications received the dual-chamber LP system as part of a prospective, multi-centre, international clinical trial (Aveir DR i2i Study, NCT05252702). Programming and diagnostics were interrogated from all de novo, non-revised, dual-chamber programmed devices at 12 months post-implant. This analysis included 302 patients (65% male; age 70 ± 13 years; weight 80 ± 19 kg; intrinsic heart rate 55 ± 7 bpm; 58% sinus node dysfunction, 27% atrioventricular block). At 12 months, devices were programmed to dual-chamber pacing (DDD(R) or DDI(R)) at a median 60 bpm rate, median 1.25 V pulse amplitude in ALP and 1.5 V in VLP, median 0.4 ms pulse width, and median i2i signal setting level 5 out of 7. Median ALP and VLP remaining battery longevities at 12 months were 4.3 and 9.1 years, with median total ALP and VLP longevities of 5.3 and 9.9 years. Base rate, pulse amplitude, pacing percentage, event rate, impedance, and i2i setting level all exhibited significant correlations with ALP and VLP longevities (P < 0.001). Programming i2i setting levels below 7 produced the greatest longevity savings. Conclusion: The first dual-chamber LP demonstrated adequate projected battery longevity after 12 months of use. Patient-specific device programming considerations, unique to leadless devices, may extend longevity.

13 March 2025 in Heart Rhythm
Verified
Journal Article
Open access
RDRahul N. Doshi
Rahul N. Doshi
JIJames E. Ip
James E. Ip
PDPascal Defaye
Pascal Defaye
VRVivek Y. Reddy
Vivek Y. Reddy
DEDerek V. Exner
Derek V. Exner
RKReinoud E. Knops
Reinoud E. Knops
Initial results were recently reported for the AVEIR DR i2i study which involved the percutaneous implantation of a novel dual-chamber leadless pacemaker (LP) system, with right atrial (RA) and ventricular (RV) LPs delivering atrioventricular synchronous pacing. Evaluate procedural outcomes and learning curve for de novo implantation of the dual-chamber LP (AVEIR DR™, Abbott). Implant procedure metrics collected during the study were analyzed, including procedural complications within 30 days post-implant. Procedural outcomes were evaluated according to implanter experience: 1-4 vs. 9+ dual-chamber LP implant procedures (i.e., initial vs. advanced implant experience). De novo dual-chamber LPs were successfully implanted in 446/452 (98.7%) patients by 126 physicians. Mean procedural duration metrics included 90±37 min introducer sheath insertion-to-removal time, 74±32 min dual-chamber procedure, 26±17 min RV LP procedure, 42±24 min RA LP procedure, and 20±13 min fluoroscopy use; between initial vs. advanced implant experience, there were reductions of 19-36% (P<0.05) in these duration metrics. There were 62 procedural complications in 50/452 (11.1%) patients (i.e., 88.9% complication free), predominantly involving cardiac arrhythmias (i.e., atrial fibrillation/flutter or complete atrioventricular block; 16/452, 3.5%). Freedom from complication significantly improved from 88.5% to 97.6% of patients (P<0.05) when comparing initial vs. advanced implant experience. In a pivotal investigational study, implantation of a dual-chamber LP system was successful in 98.7% of patients. Advanced implant experience was accompanied by improvements in procedural outcomes including reduced procedural times (introducer sheath insertion-to-removal, dual-chamber procedure, VLP and ALP procedures, and fluoroscopy) and improved freedom from complication.

19 October 2024 in Heart Rhythm
Verified
Journal Article
Open access
RDRahul N. Doshi
Rahul N. Doshi
JIJames E. Ip
James E. Ip
PDPascal Defaye
Pascal Defaye
DEDerek V. Exner
Derek V. Exner
VRVivek Y. Reddy
Vivek Y. Reddy
RKReinoud E. Knops
Reinoud E. Knops
Aveir™ DR (Abbott) is a dual-chamber leadless pacemaker (LP) system with distinct atrial and ventricular LPs (ALP, VLP) that communicate wirelessly to deliver atrioventricular synchronous pacing. Success rates of these implant-to-implant (i2i™) transmissions have not been systematically evaluated. To evaluate chronic i2i success rates in a clinical setting. Patients meeting standard dual-chamber pacing indications were enrolled and implanted with dual-chamber LP systems as part of a prospective, international clinical trial ("Aveir DR i2i Study"). The percent of successful i2i transmissions from ALP-to-VLP (A-to-V) and VLP-to-ALP (V-to-A) were interrogated from LPs in de novo patients using the device programmer at implant, discharge, and at 1-, 3-, and 6-months post-implant (1M, 3M, 6M). 399 patients completed device implant and i2i diagnostic interrogation (62% male; age 69 years; 65% sinus node dysfunction, 32% AV block). Median A-to-V and V-to-A i2i success rates exceeded 90% of beats at all time-points from implant to 6M. The minority of patients with A-to-V or V-to-A i2i success in 90% of beats throughout the 6-month evaluation period. Communication success improved significantly over time post-implant for specific subgroups.